Rhenman & Partners Asset Management Ab Olema Pharmaceuticals, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.02 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding OLMA
# of Institutions
129Shares Held
56MCall Options Held
55KPut Options Held
41.3K-
Bvf Inc San Francisco, CA9.14MShares$95.1 Million3.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY7.9MShares$82.3 Million3.36% of portfolio
-
Logos Global Management LP San Francisco, CA4.38MShares$45.6 Million4.62% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.23MShares$33.6 Million1.21% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$33.5 Million0.0% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $421M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...